Company intelligence / Profile preview

YAC BIO

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

YAC BIO has commercialized an automated hair slicing/mounting system, ultra-high-speed immunoassay platform (NeuroDetect), and offers an autism spectrum disorder screening service (ClearStrand-ASD) in Japan as of July 2025.

Therapeutic areas: Infectious DiseasesOtherNeurologyNephrology
Modalities: Diagnostic deviceMedical device
Industry: Protein Biomarker Diagnostics

Partnerships

Linus Biotechnology Inc.regional distribution collaborations

Beyond the preview

Go deeper on YAC BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YAC BIO.

Explore the full profile